Giovanni Selvaggi
Xcovery Holdings, Inc. · CEO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Giovanni Selvaggi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05665283 · A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted ConditionsXcovery Holdings, Inc. · completed · Bioequivalency · principal investigator
- Ph3NCT02767804 · eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) PatientsXcovery Holdings, Inc. · active not recruiting · Non-small Cell Lung Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:40 UTC. The ranking covers the 200 most relevant of 26 PubMed records, and a shared surname and initials can bring in a namesake. All 26 on PubMed
- Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.J Clin Oncol · 2021254 citationsRCR 12.1
- Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.JAMA Oncol · 2021240 citationsRCR 11.5
- Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.J Clin Oncol · 1999154 citationsRCR 3.7
- Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.Lancet Respir Med · 2020124 citationsRCR 4.6
- Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.Clin Cancer Res · 2005116 citationsRCR 2.5
- Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.Clin Cancer Res · 200792 citationsRCR 2.3
- A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma.Cancer Chemother Pharmacol · 201774 citationsRCR 2.4
- Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.Transplantation · 200768 citationsRCR 1.8
- Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.J Thorac Oncol · 202065 citationsRCR 2.0
- 48 citationsRCR 1.4